tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neumora Therapeutics price target raised to $5 from $4 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Neumora Therapeutics (NMRA) to $5 from $4 and keeps an Outperform rating on the shares following last week’s introduction of NMRA-861. The firm projects a U.S. launch in 2034 and risk-unadjusted NMRA-861 sales of $1.2B in 2037. It sees a favorable risk/reward at current share levels.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1